Amarin vs Esperion Therapeutics

Amarin Corporation PLC and Esperion Therapeutics are two prominent companies in the pharmaceutical industry that both specialize in developing innovative treatments for cardiovascular diseases. As competitors in the market, their stocks have garnered significant attention from investors and analysts alike. While Amarin has gained recognition for its leading drug Vascepa, Esperion Therapeutics is known for its promising cholesterol-lowering medication. The performance of these stocks is closely monitored by stakeholders seeking to capitalize on the potential growth and success of these companies in the healthcare sector.

Amarin or Esperion Therapeutics?

When comparing Amarin and Esperion Therapeutics, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Amarin and Esperion Therapeutics.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Amarin has a dividend yield of -%, while Esperion Therapeutics has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Amarin reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Esperion Therapeutics reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Amarin P/E ratio at -7.05 and Esperion Therapeutics's P/E ratio at -4.08. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Amarin P/B ratio is 0.43 while Esperion Therapeutics's P/B ratio is -1.17.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Amarin has seen a 5-year revenue growth of -0.02%, while Esperion Therapeutics's is -0.84%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Amarin's ROE at -6.09% and Esperion Therapeutics's ROE at 26.20%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $0.57 for Amarin and $2.04 for Esperion Therapeutics. Over the past year, Amarin's prices ranged from $0.56 to $1.37, with a yearly change of 144.64%. Esperion Therapeutics's prices fluctuated between $0.71 and $3.40, with a yearly change of 378.87%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.